Eurazeo SE
PAR:RF

Watchlist Manager
Eurazeo SE Logo
Eurazeo SE
PAR:RF
Watchlist
Price: 50.4 EUR 1.82%
Market Cap: 3.6B EUR

Eurazeo SE
Investor Relations

Eurazeo SE, a prominent player in the European investment landscape, is a renowned growth and private equity firm that has successfully carved out a niche in nurturing companies across varied sectors. Established in 2001 from the merger of Azeo and Eurafrance, the company emerged as a potent financial powerhouse, adept at transforming businesses into industry leaders. Eurazeo stands out for its dynamic approach to investment, leveraging its substantial capital and resources to enable businesses to scale and thrive. The firm's diversified portfolio reflects its strategic acumen in identifying and nurturing potential in industries ranging from healthcare and real estate to digital technologies and financial services.

The company's unique operational model revolves around active value creation, offering more than just capital. Eurazeo brings to the table its extensive network, strategic guidance, and expert insights, helping portfolio companies improve their operations, expand market reach, and foster innovation. With a significant portion of its earnings sourced from the long-term appreciation of these investments, Eurazeo capitalizes on its adeptness at timing the market. They carefully manage exits, often through public offerings or private sales, reaping substantial returns. Their success in orchestrating such exits underlines Eurazeo's adeptness in navigating the complexities of the investment landscape, consistently generating robust returns for its stakeholders.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Nov 6, 2025
AI Summary
Q3 2025

Fundraising Outperformance: Eurazeo raised EUR 3.2 billion in the first nine months of 2025, up 4% year-on-year, and expects full-year fundraising to exceed EUR 4 billion, well ahead of a market that is down about 10%.

Strong AUM Growth: Total assets under management rose 5% to EUR 37.4 billion, with third-party AUM up 11% and fee-paying AUM up 7%.

Successful Realizations: Realizations reached EUR 2.2 billion year-to-date, with several disposals completed above NAV and notable exits generating strong returns.

Portfolio Health: Operational metrics remain strong, with buyout companies growing 6% and growth companies delivering 15% top-line growth.

Shareholder Returns: Eurazeo is on track to return nearly EUR 1 billion to shareholders by end-2025 through EUR 400 million in dividends and EUR 600 million in share buybacks.

International Expansion: 74% of inflows came from international LPs, with growing success in Asia, the Middle East, and Europe beyond the home market.

Disciplined Gearing: Gearing increased to 23% but is expected to reduce towards 2027; management sees the company's financial position as strong and safe.

Key Financials
Fundraising
EUR 3.2 billion
Total Assets Under Management
EUR 37.4 billion
Fee-Paying Assets Under Management
Nearly EUR 28 billion
Management Fees
EUR 316 million
Private Debt Fundraising Q3
EUR 800 million
Wealth Solutions Fundraising
Close to EUR 700 million
Private Equity Deployments
EUR 800 million in Q3
Group Deployments
EUR 3.9 billion over 9 months
Private Debt Deployments Q3
EUR 900 million
Dry Powder
EUR 7.2 billion
Realizations
EUR 2.2 billion for first 9 months
Private Debt Realizations
EUR 600 million for first 9 months
Disposals (Balance Sheet)
EUR 1.1 billion year-to-date
Disposals Since 2024 (Balance Sheet)
EUR 2.2 billion
Buyout Franchise Distributions YTD
10% of NAV
Buyout Companies Average Growth
6% over 9 months
Growth Companies Top Line Growth
15% average
Growth Fund IV Portfolio Revenue Growth
37% average in first 9 months
Doctolib Profitability
Reached profitability in Q3 2025
DPI (Kurma BioFund III)
75%
Shareholder Returns by End-2025
Close to EUR 1 billion (EUR 400 million in dividends, EUR 600 million in buybacks)
Share Buybacks
EUR 300 million already completed in 2025
Gearing
23% (EUR 1.6 billion in net financial debt)
Earnings Call Recording
Other Earnings Calls
2025
2023
2022
2020
2018

Management

Mr. Christophe M. Baviere
Co-CEO & Co-Chairman of the Executive Board
No Bio Available
Mr. William Kadouch-Chassaing
Co-CEO & Co-Chairman of Executive Board
No Bio Available
Mr. Olivier Millet
Member of the Executive Board and Managing Partner of Small-mid buyout & NovSanté
No Bio Available
Ms. Laurence Branthomme
CFO & Head of Operations
No Bio Available
Ms. Sophie Flak
Member of Executive Board and Managing Partner of Sustainability & Impact
No Bio Available
Mr. Arnaud Berthe
Managing Director of Group Accounting
No Bio Available
Ms. Valérie Ducourty
Managing Director of Corporate Financing
No Bio Available
Mr. Jean-Daniel Vouille
Chief Technical Officer
No Bio Available
Ms. Domitille Doat-Le Bigot
Chief Digital & Information Officer
No Bio Available
Mr. Pierre Bernardin
Director & Head of Investor Relations
No Bio Available

Contacts

Address
ILE-DE-FRANCE
Paris
1 Rue de Georges Berger
Contacts
+33144150111.0
www.eurazeo.com